Latest on Ultrasound Renal Denervation

Published: 22 June 2022

  • Views:

    Views Icon 4003
  • Likes:

    Heart Icon 7
  • episode_image
    Part 3 | Session 1 ACC 2022 Symposium
    Michael Weber, Felix Mahfoud, Ajay J Kirtane, Michael Bloch
  • episode_image
    Part 3 | Session 2 TCT 2021 Symposium
    Chandan Devireddy, Ajay J Kirtane, Felix Mahfoud, Naomi Fisher

Overview

Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.

 

This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.

 

The PARADISETM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
This educational content is supported by:

What you will learn:

  • How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
  • The clinical evidence supporting uRDN and its implications for the field of hypertension
  • The process for building a uRDN centre and therapy network

This page is designed for:

  • Interventional cardiologists
  • General cardiologists
  • Hypertension specialists
  • Nephrologists
  • Interventional radiologists

More from this programme

Part 3

Discussion With Experts

Part 5

Patient Perspective & Provider Referral Development

Understand patient preference and referral development

Part 6

RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension

Faculty Biographies

Andrew SP Sharp

Andrew SP Sharp

Consultant Cardiologist

Prof Andrew Sharp is a Consultant Cardiologist at the University Hospital of Wales, Cardiff, UK. Andrew qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant Cardiologist at the Royal Devon and Exeter Hospital in 2011 and Honorary Associate Professor by the University of Exeter in 2018 before moving to the University Hospital of Wales in Cardiff in the summer of 2019.

Andrew conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training, completing the prestigious Milan-Imperial Interventional Cardiology Fellowship programme. Dr Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and his current research interests include device-based treatments for hypertension, pulmonary embolism, intracoronary imaging and coronary physiology.

Andrew's specialist interests include the pharmacological and interventional…

View full profile